Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 267 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: contrast-enhanced magnetic resonance imaging Clear all
Completed Early Phase 1 Interventional

PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

NCT03232164
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasm
Interventions
18F-DCFPyL PET
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.

NCT00539253
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
gadobenate dimeglumine (MultiHance)
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

NCT01104584
View directory record Official record
Conditions
Breast Cancer
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

NCT02199236
View directory record Official record
Conditions
Rectal or Anal Cancer
Interventions
endorectal brachytherapy, concurrent capecitabine or 5-FU, Questionnaires
Radiation · Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)

NCT01871545
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 1, 2026, 7:14 PM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

NCT04396860
View directory record Official record
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Procedure · Biological · Device + 3 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
285
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Early Phase 1 Interventional

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

NCT00881218
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Oct 1, 2026, 7:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania

NCT04085510
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Neoplasms, Neoplasms
Interventions
Contrast-enhanced mammogram
Device
Lead sponsor
Wendie Berg
Other
Eligibility
30 Years to 85 Years · Female only
Enrollment
1,647 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
3
States / cities
Cranberry Township, Pennsylvania • Monroeville, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 1, 2026, 7:14 PM EDT
Withdrawn Not applicable Interventional

High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer

NCT03514927
View directory record Official record
Conditions
Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II, Prostate Cancer Stage III
Interventions
Contrast-Enhanced Ultrasound, High-Intensity Focused Ultrasound, Laboratory Biomarker Analysis, Multiparametric Magnetic Resonance Imaging, Radical Prostatectomy
Procedure · Device · Other
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 1, 2026, 7:14 PM EDT
Recruiting Not applicable Interventional

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

NCT04442724
View directory record Official record
Conditions
Bladder Cancer, Urinary Bladder Neoplasm, Urologic Neoplasms, Neoplasms, Urinary Bladder Diseases
Interventions
Fiducial marker placement, Multiparametric MRI (mpMRI)
Procedure · Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 1, 2026, 7:14 PM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients

NCT01092754
View directory record Official record
Conditions
Pathological Processes
Interventions
MRI, Gadoversetamide
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
2 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
12
States / cities
Little Rock, Arkansas • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease

NCT01989195
View directory record Official record
Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 1, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

NCT04867954
View directory record Official record
Conditions
Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions
Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 1, 2026, 7:14 PM EDT
Terminated Not applicable Interventional

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

NCT02269111
View directory record Official record
Conditions
Tumors Metastatic to Brain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
diffusion-weighted magnetic resonance imaging, chemical exchange saturation transfer magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, dynamic susceptibility contrast-enhanced magnetic resonance imaging
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 1, 2026, 7:14 PM EDT
Completed No phase listed Observational

Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)

NCT00957099
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
35 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 1, 2026, 7:14 PM EDT
Recruiting Phase 2 Interventional

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

NCT04981509
View directory record Official record
Conditions
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Computed Tomography with Contrast, Erlotinib, Magnetic Resonance Imaging, Positron Emission Tomography, Sodium Fluoride F-18
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 1, 2026, 7:14 PM EDT
Recruiting No phase listed Observational

Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies

NCT03099850
View directory record Official record
Conditions
Pancreatitis
Interventions
Data Management and Monitoring
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2,345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 1, 2026, 7:14 PM EDT
Completed No phase listed Observational

Multicenter Myocardial Viability Trial

NCT00661232
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
CHI St. Luke's Health, Texas
Other
Eligibility
21 Years to 85 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma

NCT03922984
View directory record Official record
Conditions
Glioblastoma
Interventions
MRI with Arterial Spin Labeling (ASL)
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 1, 2026, 7:14 PM EDT
Active, not recruiting No phase listed Observational

International Consortium for Multimodality Phenotyping in Adults With Non-compaction

NCT04424030
View directory record Official record
Conditions
Non-Compaction Cardiomyopathy
Interventions
Echocardiography, Magnetic resonance imaging (MRI), Computed tomography (CT)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
3
States / cities
Palo Alto, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 1, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla

NCT00588679
View directory record Official record
Conditions
Prostate Cancer, MRI
Interventions
Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 1, 2026, 7:14 PM EDT